<DOC>
	<DOCNO>NCT00942266</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , fluorouracil leucovorin calcium , work different way stop growth tumor cell , either kill cell stop dividing . It yet know dose vorinostat effective give together combination chemotherapy treat patient metastatic colorectal cancer . PURPOSE : This randomized phase II trial study best dose vorinostat see well work give together fluorouracil leucovorin calcium treat patient metastatic colorectal cancer respond previous treatment .</brief_summary>
	<brief_title>Vorinostat , Fluorouracil , Leucovorin Calcium Treating Patients With Metastatic Colorectal Cancer That Has Not Responded Previous Treatment</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Describe 2-months progression free rate vorinostat 800mg/day x 3 combination 5-FU/L V every 2 week . ( Arm I ) II . Describe 2-months progression free rate vorinostat 1400mg/day x 3 combination 5-FU/L V every 2 week . ( Arm II ) SECONDARY OBJECTIVES : I . Describe response rate Arm 1 Arm 2 study . II . Estimate median progression free survival arm study . III . Describe overall survival Arm 1 Arm 2 study . IV . Describe toxicities Arm 1 Arm 2 study . V. Describe vorinostat pharmacokinetics Arm 1 Arm 2 study . VI . Describe 5-FU steady state pharmacokinetics Arm 1 Arm 2 study . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive low-dose oral vorinostat daily day 1-3 , leucovorin calcium IV 2 hour day 2 , fluorouracil IV 46 hour day 2 3 . Courses repeat every 2 week absence disease progression unacceptable toxicity . ARM II : Patients receive high-dose oral vorinostat daily day 1-3 leucovorin calcium fluorouracil arm I . Courses repeat every 2 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow 30 day every 3 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Inclusion Patients must histologically cytologically confirm colorectal adenocarcinoma metastatic fail standard treatment standard treatment available Patients fluoropyrimidinerefractory disease ; radiographic evidence progression within 4 week last dose fluoropyrimidinebased regimen ( least 6 week fluoropyrimidinebased treatment ) Patients receive progressed ( proved intolerant ) oxaliplatin irinotecan ; progression within 6 month oxaliplatinbased therapy irinotecanbased therapy acceptable eligibility Patients KRAS wildtype unknown KRAS status tumor progress within 6 month last cetuximab panitumumabbased therapy ; prior cetuximab therapy require KRAS mutant tumor ECOG performance status = &lt; 2 Life expectancy &gt; = 12 week Ability understand willingness sign write informed consent document Ability swallow pill Absolute neutrophil count &gt; = 1,500/uL Platelets &gt; = 100,000/uL Total bilirubin = &lt; institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) = &lt; 3 x institutional upper limit normal absence metastatic disease liver = &lt; 5 x institutional upper limit normal set metastatic disease liver Creatinine = &lt; 1.5 x institutional upper limit normal Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Males undergo study treatment also agree adequate measure contraception ( partner contraception use condom abstinence , vasectomy ) Exclusion Patients chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover significant adverse event due agent administer 3 week earlier Patients may receive investigational agent Patients know brain metastasis exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition vorinostat agent use study Greater Grade 2 neuropathy define CTCAE version 3.0 Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Baseline EKG QTc prolongation grade 2 high CTCAE version 3.0 Pregnant woman exclude study ; breastfeed discontinue mother treated vorinostat Patients take valproic acid histone deacetylase inhibitor , least 4 week prior enrollment Patients know HIV infection know active viral hepatitis Prior treatment vorinostat Other nonstudy medication know increase QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>